Skip to main content

Table 2 Short-term and long-term outcome

From: Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)

Response TAC + ZA
N = 122 (49.6%)
TAC
N = 124 (50.4%)
P value
pCR breast and LN
 Yes 16 (13.3%) 16 (13.2%)  
 No 104 (86.7%) 105 (86.8%) 0.980
Miller and Payne
 1 19 (15.8%) 18 (14.8%)  
 2 35 (29.2%) 31 (25.4%)  
 3 24 (20.0%) 25 (20.5%)  
 4 21 (17.5%) 25 (20.5%)  
 5 21 (17.5%) 23 (18.9%) 0.950
Recurrence
 Total 29 (23.8%) 20 (16.1%) 0.134
 Local 5 (4.1%) 5 (4.0%) 0.979
 Regional 7 (5.7%) 4 (3.2%) 0.341
 Distant 27 (22.1%) 17 (13.7%) 0.085
 Second primary tumor 5 (4.1%) 5 (4.0%) 0.979
Death
 Yes 23 (18.9%) 11 (8.9%)  
 No 99 (81.1%) 113 (91.1%) 0.023
Cause of death
 Breast cancer 22 (95.7%) 11 (91.6%) 0.630
 Other 1 (4.3%) 1 (8.3%)  
  1. TAC docetaxel, doxorubicin, and cyclophosphamide, ZA zoledronic acid, pCR pathologic complete response, LN lymph nodes, MP Miller and Payne
  2. the italicized data have a significance of > 0.05